Cardiff Oncology’s onvansertib shows efficacy in Phase 2 colorectal cancer trial

Cardiff Oncology (CRDF) announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer, or mCRC.